Bioverativ acquires True North Therapeutics and with it TNT 009 an innovative treatment for cold agglutinin disease.

Bioverativ Inc. a global biotechnology company which was spun out of Biogen , is focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders and has announced that it has entered into a definitive agreement to acquire True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash. True North investors are also eligible to receive additional payments of up to $425 million contingent on the achievement of future development, regulatory and sales milestones. As part of the acquisition, Bioverativ will obtain worldwide rights to True North�s lead candidate, TNT 009, a first-in-class monoclonal antibody in development to treat cold agglutinin disease (CAD). CAD is a rare and chronic hemolytic condition that often leads to severe anemia, requiring numerous transfusions, and can result in life-threatening thrombotic events. There are no approved therapies for CAD, which occurs in approximately 16 people per million globally, including an estimated 5,000 people in the United States.